Unsere Lösungen

Wir haben für alles eine Lösung – und die entsprechende Erfahrung. In unseren derzeit sieben Kompetenzbereichen stehen wir Ihnen mit unserem umfassenden Know-how mit Rat und Tat zur Seite.

Alle Lösungen

Software

Software

Mit unserem Werum PAS-X MES – vor Ort oder in der Cloud installiert – und unseren Softwarelösungen für Datenanalyse, Track & Trace, vernetzte Fabriken und intelligente Verpackungen sind wir der weltweit führende Anbieter und Partner der Pharma- und Biotechindustrie.

Übersicht Software

Transportsysteme

Transportsysteme

Wir sind Spezialisten für komplette Transportsysteme im Bereich Pharma- und Medizinprodukte. Unsere Lösungen sind maßgebend im Bereich des kontaktlosen und sicheren Transports von z.B. Glasspritzen.

Übersicht Transportsysteme

Inspektionsmaschinen

Inspektion

Als weltweit führender Inspektionsexperte entwicklen wir Lösungen für die Pharma und Biotechindustrie. Unser Angebot reicht von Hochleistungsmaschinen und Halbautomaten über Laboreinheiten bis Inspektionsapplikationen für die Inprozesskontrolle.

Übersicht Inspektion

Maschinen-Finder

Verpackungsmaschinen

Verpackungsmaschinen

Wir sind führender Anbieter von Verpackungsmaschinen für flüssige und feste pharmazeutische- sowie für medizinische Produkte. Mit unseren Blister-, Sachet- und Stickpackmaschinen bieten wir Lösungen für Primärverpackungen. Unsere Side- und Topload-Kartonierer setzen weltweit Standards für die Sekundärverpackung.

Übersicht Verpackungsmaschinen

K.Pak Topload Case Packer

Introducing our latest solution from Körber; the K.Pak Topload Case Packer! Created specifically for the pharmaceutical industry, the K.Pak solution provides operator-friendly machines to complete any production line. Our solution focuses on innovative technology, high-quality design and expert handling and packaging of your product. It’s time to start connecting the dots with Körber!

Verpackungslösungen

Verpackungslösungen

Als langjährige Spezialisten entwickeln wir Verpackungslösungen für innovative und hochwertige Pharma-Sekundärverpackungen aus Karton. Wir bieten Ihnen Lösungen für Fälschungssicherheit, Standard- Faltschachteln und vieles mehr.

Übersicht Verpackungslösungen

Beratung

Beratung

Unsere Experten beraten Sie nach der Analyse Ihrer Anforderungen, zeigen Ihnen Optimierungspotenziale auf und unterstützen Sie bei der Implementierung von Projekten in allen Bereichen der Pharma-, Biotech- und Medizinproduktindustrie.

Übersicht Beratung

Thomas Zahel

Blog

Successful process characterization in biotech: A how-to-guide in 7 steps

Process validation (PV) aims at reassuring a manufacturer of constant product quality. It is also a regulatory requirement to achieve licensure of a pharmaceutical product. Failing to efficiently plan and execute activities on that stage leads to increased time-to-market. 

The fact that in the 22 pages of the latest FDA guidance document on process validation, statistical approaches and the need of statisticians in a multi-disciplinary team is mentioned no less but 15 times underscores the importance of showing statistical confidence about the chosen control strategy for critical process parameters (CPPs), input material and measured critical quality attributes (CQAs) during the manufacturing process (ICH Q8 (R2) 2009, 8). 

Figure 1: The aim of process validation is to identify the impact of process parameters of individual unit operations on the final drug substance product quality.

Every process characterization (PC) strategy aims to identify process parameters that impact product quality and yield:

  • Identify interactions between process parameters and critical quality attributes
  • Justify and if necessary adjust manufacturing operating ranges and acceptance criteria
  • Ensure that the process delivers a product with reproducible yields and purity

Successful PC is achieved when:

  • Scope, deliverables and timelines are well aligned between all stakeholders
  • Evidence-based decision making is increased and influence of the loudest voice during risk assessments is reduced
  • Equivalence testing is employed to identify potential offsets between scales
  • Impact of PPs onto CQAs is identified at minimal experimental effort
  • A model-based control strategy (e.g. PAR) is established for each unit operation
  • A holistic control strategy, taking the mutual interplay of all unit operations into account, is achieved using integrated process modelling. This shows that the manufacturing process is well understood and consistently delivers highest product quality in drug substance (DS) in the future.

In the following we show you how to successfully conduct a process characterization study (PCS) in 7 steps:

Figure 2: Tasks and typical timeline of a process characterization study

1. Achieve project transparency with a Process Validation Master Plan 

You should start with a plan comprising all intended steps and goals. Data collection and evaluation need to be aligned as usually many internal stakeholders (process development, manufacturing, and manufacturing science departments) and external like CRO & CMO are involved. Transparent information about timelines, data flows, interfaces to departments/ stakeholders and deliverables guarantee timely delivery of the final PCS report and allows to include it into BLA filing.

With PAS-X CMC Consulting, Körber supports in the development of requirements for each task and herein delivers a detailed timeline that ensures timely delivery of regulatory documents and finish process characterization studies.

    

2. Avoid unpleasant side effects and conduct a risk assessment

The aim of a Failure Mode and Effects Analysis (FMEA) is to pre-select potential impacting factors for further experimental investigation and rate other factors as being not critical based on process expertise. It is very important to incorporate data-based prior information of occurrences and severities. By that, you reduce the impact of individual opinions on the final FMEA outcome. 

Our PAS-X CMC Consulting experts assist in regulatory compliant qualitative and quantitative risk analysis according to ICH Q9.